{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:41:22Z","timestamp":1793900482756,"version":"4.8.0"},"reference-count":556,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,26]],"date-time":"2027-02-26T00:00:00Z","timestamp":1803600000000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["P 01CA275740"],"award-info":[{"award-number":["P 01CA275740"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"NIAAA","doi-asserted-by":"publisher","award":["5R01AA030180"],"award-info":[{"award-number":["5R01AA030180"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["5I01BX005730"],"award-info":[{"award-number":["5I01BX005730"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK6BX004477"],"award-info":[{"award-number":["IK6BX004477"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK139587"],"award-info":[{"award-number":["R01DK139587"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK115377"],"award-info":[{"award-number":["R01DK115377"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.pharmr.2026.100120","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:19:11Z","timestamp":1769732351000},"page":"100120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0050-372X","authenticated-orcid":false,"given":"Huiping","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-1902","authenticated-orcid":false,"given":"Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7409-647X","authenticated-orcid":false,"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip B.","family":"Hylemon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib1","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s00125-016-3940-5","article-title":"Hepatic glucose and lipid metabolism","volume":"59","author":"Jones","year":"2016","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib2","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.18203\/2319-2003.ijbcp20184211","article-title":"The role of liver in metabolism: an updated review with physiological emphasis","volume":"7","author":"Alamri","year":"2018","journal-title":"Int J Basic Clin Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100120_bib3","author":"Kalra"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/17425255.2012.658041","article-title":"The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury","volume":"8","author":"Amacher","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-024-02072-z","article-title":"Liver diseases: epidemiology, causes, trends and predictions","volume":"10","author":"Gan","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib7","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.cgh.2024.10.026","article-title":"Global trend of MASH-associated liver cancer: a systematic analysis from the global burden of disease 2021","volume":"23","author":"Danpanichkul","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100120_bib8","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.clinthera.2023.08.019","article-title":"Intersection of coronavirus disease 2019 and alcohol-associated liver disease: a review of emerging trends and implications","volume":"45","author":"Aby","year":"2023","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib9","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.dld.2022.07.007","article-title":"Covid-19 and alcohol associated liver disease","volume":"54","author":"Deutsch-Link","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176345","article-title":"Alcohol-associated liver disease","volume":"134","author":"Mackowiak","year":"2024","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3892\/mmr.2024.13375","article-title":"Gut-liver axis in liver disease: from basic science to clinical treatment (Review)","volume":"31","author":"Wang","year":"2025","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41392-022-00974-4","article-title":"Microbiota in health and diseases","volume":"7","author":"Hou","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41522-022-00352-6","article-title":"Host-microbiome interactions: gut-Liver axis and its connection with other organs","volume":"8","author":"Anand","year":"2022","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.gastro.2014.10.042","article-title":"Gut-liver axis in alcoholic liver disease","volume":"148","author":"Szabo","year":"2015","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41579-023-00904-3","article-title":"The gut-liver axis and gut microbiota in health and liver disease","volume":"21","author":"Hsu","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib18","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1097\/HEP.0000000000000924","article-title":"Gut-liver axis: recent concepts in pathophysiology in alcohol-associated liver disease","volume":"80","author":"Raya Tonetti","year":"2024","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib19","doi-asserted-by":"crossref","first-page":"878","DOI":"10.4254\/wjh.v16.i6.878","article-title":"Importance of the gut microbiota in the gut-liver axis in normal and liver disease","volume":"16","author":"Kotlyarov","year":"2024","journal-title":"World J Hepatol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.numecd.2012.02.007","article-title":"Gut\u2014liver axis: the impact of gut microbiota on non alcoholic fatty liver disease","volume":"22","author":"Compare Compare","year":"2012","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100120_bib21","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00018-008-7568-6","article-title":"Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics","volume":"65","author":"Hofmann","year":"2008","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbalip.2016.08.012","article-title":"Mitochondrial cholesterol import","volume":"1862","author":"Elustondo","year":"2017","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10863-014-9592-6","article-title":"Mitochondrial cholesterol: mechanisms of import and effects on mitochondrial function","volume":"48","author":"Martin","year":"2016","journal-title":"J Bioenerg Biomembr"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100120_bib24","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.bbamcr.2006.09.001","article-title":"Peroxisomes and bile acid biosynthesis","volume":"1763","author":"Ferdinandusse","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmr.2026.100120_bib25","first-page":"83","article-title":"Metabolic interplay between peroxisomes and other subcellular organelles including mitochondria and the endoplasmic reticulum","volume":"3","author":"Wanders","year":"2015","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.livres.2019.05.001","article-title":"The acidic pathway of bile acid synthesis: not just an alternative pathway(white star)","volume":"3","author":"Pandak","year":"2019","journal-title":"Liver Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00418-006-0239-5","article-title":"Differential hepatocellular zonation pattern of cholesterol 7alpha-hydroxylase (Cyp7a1) and sterol 12alpha-hydroxylase (Cyp8b1) in the mouse","volume":"127","author":"Wang","year":"2007","journal-title":"Histochem Cell Biol"},{"issue":"7641","key":"10.1016\/j.pharmr.2026.100120_bib28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature21065","article-title":"Single-cell spatial reconstruction reveals global division of labour in the mammalian liver","volume":"542","author":"Halpern","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib29","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.32408","article-title":"Liver zonation, revisited","volume":"76","author":"Paris","year":"2022","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100120_bib30","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1194\/jlr.M071183","article-title":"Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans","volume":"57","author":"Takahashi","year":"2016","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2024-100074","article-title":"Bile acids regulation of cellular stress responses in liver physiology and diseases","volume":"2","author":"Li","year":"2024","journal-title":"eGastroenterology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib32","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/hep.21528","article-title":"Human and rat bile acid-CoA:amino acid N-acyltransferase are liver-specific peroxisomal enzymes: implications for intracellular bile salt transport","volume":"45","author":"Pellicoro","year":"2007","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100120_bib33","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/jat.3645","article-title":"Species differences in bile acids II. Bile acid metabolism","volume":"38","author":"Thakare","year":"2018","journal-title":"J Appl Toxicol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib34","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.3390\/molecules27061983","article-title":"A recent ten-year perspective: bile acid metabolism and signaling","volume":"27","author":"Shulpekova","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib35","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40168-021-01101-1","article-title":"Review: microbial transformations of human bile acids","volume":"9","author":"Guzior","year":"2021","journal-title":"Microbiome"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-024-00914-3","article-title":"The changing metabolic landscape of bile acids\u2014keys to metabolism and immune regulation","volume":"21","author":"Mohanty","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7797","key":"10.1016\/j.pharmr.2026.100120_bib37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41586-020-2047-9","article-title":"Global chemical effects of the microbiome include new bile-acid conjugations","volume":"579","author":"Quinn","year":"2020","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100120_bib38","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1016\/j.cell.2025.05.010","article-title":"A microbial amino-acid-conjugated bile acid, tryptophan-cholic acid, improves glucose homeostasis via the orphan receptor MRGPRE","volume":"188","author":"Lin","year":"2025","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib39","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1128\/AEM.72.3.1729-1738.2006","article-title":"Bile salt hydrolase activity in probiotics","volume":"72","author":"Begley","year":"2006","journal-title":"Appl Environ Microbiol"},{"issue":"36","key":"10.1016\/j.pharmr.2026.100120_bib40","doi-asserted-by":"crossref","first-page":"13580","DOI":"10.1073\/pnas.0804437105","article-title":"Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome","volume":"105","author":"Jones","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","article-title":"Bile salt biotransformations by human intestinal bacteria","volume":"47","author":"Ridlon","year":"2006","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1128\/aem.45.1.141-147.1983","article-title":"Cooperative formation of omega-muricholic acid by intestinal microorganisms","volume":"45","author":"Eyssen","year":"1983","journal-title":"Appl Environ Microbiol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"Wahlstr\u00f6m","year":"2016","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib44","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1194\/jlr.R000042","article-title":"Bile salts of vertebrates: structural variation and possible evolutionary significance","volume":"51","author":"Hofmann","year":"2010","journal-title":"J Lipid Res"},{"issue":"5418","key":"10.1016\/j.pharmr.2026.100120_bib45","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"issue":"5418","key":"10.1016\/j.pharmr.2026.100120_bib46","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol Cell"},{"issue":"1\u20132","key":"10.1016\/j.pharmr.2026.100120_bib48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsbmb.2012.04.008","article-title":"Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19","volume":"132","author":"Miyata","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib49","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2015.07.029","article-title":"The FXR-FGF19 gut-liver axis as a novel \u201chepatostat\u201d","volume":"149","author":"Avila","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib50","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.gastro.2018.06.038","article-title":"An FXR agonist reduces bile acid synthesis independently of increases in FGF19 in healthy volunteers","volume":"155","author":"Al-Khaifi","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib51","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jhep.2021.07.029","article-title":"Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver","volume":"75","author":"Gadaleta","year":"2021","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib52","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol Cell"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166121","article-title":"Liver X receptors and liver physiology","volume":"1867","author":"Russo-Savage","year":"2021","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/nu7010045","article-title":"Understanding how commensal obligate anaerobic bacteria regulate immune functions in the large intestine","volume":"7","author":"Maier","year":"2014","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1172\/JCI108271","article-title":"Degradation of blood group antigens in human colon ecosystems. II. A gene interaction in man that affects the fecal population density of certain enteric bacteria","volume":"57","author":"Hoskins","year":"1976","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib56","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1194\/jlr.R088989","article-title":"Microbial impact on cholesterol and bile acid metabolism: current status and future prospects","volume":"60","author":"Kriaa","year":"2019","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib57","first-page":"289","article-title":"Intestinal microbial metabolism of phosphatidylcholine: a novel insight in the cardiovascular risk scenario","volume":"4","author":"Ierardi","year":"2015","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib58","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","article-title":"Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism","volume":"7","author":"Morrison","year":"2016","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib59","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02032-23","article-title":"Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases","volume":"15","author":"Zeng","year":"2024","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s44355-025-00029-9","article-title":"Exploring the trimethylamine pathway in advanced chronic liver disease","volume":"2","author":"B\u00fcrki","year":"2025","journal-title":"npj Gut Liver"},{"key":"10.1016\/j.pharmr.2026.100120_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2025.1565609","article-title":"An overview of basic pathophysiological interactions between gut bacteria and their host","volume":"12","author":"Simonson","year":"2025","journal-title":"Front Nutr"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib62","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-019-0495-2","article-title":"Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study","volume":"25","author":"Depommier","year":"2019","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib63","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.cell.2024.03.034","article-title":"Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway","volume":"187","author":"Nie","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib64","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.chembiol.2018.10.003","article-title":"Bile acid 7alpha-Dehydroxylating gut bacteria secrete antibiotics that inhibit Clostridium difficile: role of secondary bile acids","volume":"26","author":"Kang","year":"2019","journal-title":"Cell Chem Biol"},{"issue":"7484","key":"10.1016\/j.pharmr.2026.100120_bib65","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature12820","article-title":"Diet rapidly and reproducibly alters the human gut microbiome","volume":"505","author":"David","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib66","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1038\/ncomms7342","article-title":"Fat, fibre and cancer risk in African Americans and rural Africans","volume":"6","author":"O\u2019Keefe","year":"2015","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib67","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1017\/S0007114519000680","article-title":"Gut Prevotella as a possible biomarker of diet and its eubiotic versus dysbiotic roles: a comprehensive literature review","volume":"122","author":"Precup","year":"2019","journal-title":"Br J Nutr"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib68","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuad039","article-title":"Faecalibacterium: a bacterial genus with promising human health applications","volume":"47","author":"Mart\u00edn","year":"2023","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.pharmr.2026.100120_bib69","article-title":"Christensenella minuta, a new candidate next-generation probiotic: current evidence and future trajectories","volume":"14","author":"Ignatyeva","year":"2023","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib70","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12915-019-0699-4","article-title":"The human gut bacteria Christensenellaceae are widespread, heritable, and associated with health","volume":"17","author":"Waters","year":"2019","journal-title":"BMC Biol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100120_bib71","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.3390\/ijms22126242","article-title":"Interaction between lipopolysaccharide and gut microbiota in inflammatory bowel diseases","volume":"22","author":"Candelli","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib72","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1286-4579(02)01604-0","article-title":"Structure and function of lipopolysaccharides","volume":"4","author":"Erridge","year":"2002","journal-title":"Microbes Infect"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib73","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3390\/nu12051474","article-title":"The Firmicutes\/Bacteroidetes Ratio: a relevant marker of gut dysbiosis in obese patients?","volume":"12","author":"Magne","year":"2020","journal-title":"Nutrients"},{"issue":"42","key":"10.1016\/j.pharmr.2026.100120_bib74","doi-asserted-by":"crossref","first-page":"29749","DOI":"10.1074\/jbc.274.42.29749","article-title":"Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor\/9-cis-retinoic acid receptor heterodimer","volume":"274","author":"Grober","year":"1999","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib75","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0958-1669(99)00031-2","article-title":"Nuclear receptor regulation of cholesterol and bile acid metabolism","volume":"10","author":"Repa","year":"1999","journal-title":"Curr Opin Biotechnol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib76","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0006-291X(02)02550-0","article-title":"Identification of membrane-type receptor for bile acids (M-BAR)","volume":"298","author":"Maruyama","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib77","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1074\/jbc.M209706200","article-title":"A G protein-coupled receptor responsive to bile acids","volume":"278","author":"Kawamata","year":"2003","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib78","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1073\/pnas.051551698","article-title":"The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity","volume":"98","author":"Staudinger","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5571","key":"10.1016\/j.pharmr.2026.100120_bib79","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1126\/science.1070477","article-title":"Vitamin D receptor as an intestinal bile acid sensor","volume":"296","author":"Makishima","year":"2002","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib80","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hep.24681","article-title":"Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes","volume":"55","author":"Studer","year":"2012","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib81","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.dld.2019.03.020","article-title":"The role of sphingosine kinase 2 in alcoholic liver disease","volume":"51","author":"Kwong","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib82","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3390\/cells10112806","article-title":"Bile acid receptors and the gut-liver axis in nonalcoholic fatty liver disease","volume":"10","author":"Xue","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib83","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/thy.2007.0255","article-title":"Bile acids and the membrane bile acid receptor TGR5\u2014connecting nutrition and metabolism","volume":"18","author":"Thomas","year":"2008","journal-title":"Thyroid"},{"key":"10.1016\/j.pharmr.2026.100120_bib84","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.aninu.2024.12.003","article-title":"Different types of bile acids exhibit opposite regulatory effects on lipid metabolism in finishing pigs through bile acid receptors","volume":"21","author":"Hu","year":"2025","journal-title":"Anim Nutr"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib85","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab"},{"issue":"8049","key":"10.1016\/j.pharmr.2026.100120_bib86","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41586-024-08379-9","article-title":"hosts. Host metabolism balances microbial regulation of bile acid signalling","volume":"638","author":"Won","year":"2025","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib87","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0022-2275(20)30141-3","article-title":"Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor","volume":"43","author":"Kliewer","year":"2002","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib88","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/hep.21458","article-title":"The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells","volume":"45","author":"Keitel","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib89","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbrc.2008.04.171","article-title":"Expression and function of the bile acid receptor TGR5 in Kupffer cells","volume":"372","author":"Keitel","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib90","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000324127","article-title":"TGR5 in the biliary tree","volume":"29","author":"Keitel","year":"2011","journal-title":"Dig Dis"},{"issue":"33","key":"10.1016\/j.pharmr.2026.100120_bib91","doi-asserted-by":"crossref","first-page":"54378","DOI":"10.18632\/oncotarget.17533","article-title":"The G-protein-coupled bile acid receptor Gpbar1 (TGR5) protects against renal inflammation and renal cancer cell proliferation and migration through antagonizing NF-\u03baB and STAT3 signaling pathways","volume":"8","author":"Su","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmr.2026.100120_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.151671","article-title":"Role of bile acid-dependent Takeda G-coupled protein receptor 5 (TGR5) in regulating AMPK expression in human podocytes","volume":"759","author":"Rachubik","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib93","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrendo.2018.13","article-title":"Adipose tissue: bile acid-TGR5 axis promotes beiging","volume":"14","author":"Bradley","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100120_bib94","doi-asserted-by":"crossref","first-page":"10322","DOI":"10.1074\/jbc.RA118.002733","article-title":"The exercise-inducible bile acid receptor Tgr5 improves skeletal muscle function in mice","volume":"293","author":"Sasaki","year":"2018","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib95","first-page":"51","article-title":"Lithocholic acid promotes skeletal muscle regeneration through the TGR5 receptor","volume":"55","author":"Sun","year":"2023","journal-title":"Acta Biochim Biophys Sin"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib96","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0014-5793(97)01301-X","article-title":"Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids","volume":"417","author":"An","year":"1997","journal-title":"FEBS Lett"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib97","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0006-291X(90)92072-8","article-title":"Isolation of immediate-early differentiation mRNAs by enzymatic amplification of subtracted cDNA from human endothelial cells","volume":"167","author":"Hla","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib98","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1042\/bj3300605","article-title":"Sphingosine 1-phosphate signalling through the G-protein-coupled receptor Edg-1","volume":"330","author":"Zondag","year":"1998","journal-title":"Biochem J"},{"issue":"S30-31","key":"10.1016\/j.pharmr.2026.100120_bib99","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/(SICI)1097-4644(1998)72:30\/31+<147::AID-JCB19>3.0.CO;2-F","article-title":"Signaling mechanisms and molecular characteristics of G protein-coupled receptors for lysophosphatidic acid and sphingosine 1-phosphate","volume":"72 Suppl 30-31","author":"An","year":"1998","journal-title":"J Cell Biochem"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0163-7258(00)00084-X","article-title":"Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors","volume":"88","author":"Pyne","year":"2000","journal-title":"Pharmacol Ther"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100120_bib101","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1111\/febs.12446","article-title":"Sphingosine-1-phosphate receptor 2","volume":"280","author":"Adada","year":"2013","journal-title":"FEBS Journal"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib102","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1158\/0008-5472.CAN-04-2311","article-title":"The G protein-coupled receptor S1P2 regulates Rho\/Rho kinase pathway to inhibit tumor cell migration","volume":"65","author":"Lepley","year":"2005","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib103","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jcb.20127","article-title":"Structural and functional characteristics of S1P receptors","volume":"92","author":"Sanchez","year":"2004","journal-title":"J Cell Biochem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib104","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12672-023-00611-8","article-title":"Sphingosine 1-phosphate receptor 2 promotes the onset and progression of non-alcoholic fatty liver disease-related hepatocellular carcinoma through the PI3K\/AKT\/mTOR pathway","volume":"14","author":"Wang","year":"2023","journal-title":"Discov Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12964-022-00971-8","article-title":"Sphingosine 1-phosphate receptor 2 mediated early stages of pancreatic and systemic inflammatory responses via NF-kappa B activation in acute pancreatitis","volume":"20","author":"Yang","year":"2022","journal-title":"Cell Commun Signal"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib106","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1194\/jlr.M004929","article-title":"Bile acids regulate hepatic gluconeogenic genes and farnesoid X receptor via G(alpha)i-protein-coupled receptors and the AKT pathway","volume":"51","author":"Cao","year":"2010","journal-title":"J Lipid Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib107","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hep.20942","article-title":"Conjugated bile acids promote ERK1\/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes","volume":"42","author":"Dent","year":"2005","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib108","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.ajpath.2018.05.015","article-title":"Conjugated bile acids promote invasive growth of esophageal adenocarcinoma cells and cancer stem cell expansion via sphingosine 1-phosphate receptor 2-mediated yes-associated protein activation","volume":"188","author":"Liu","year":"2018","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib109","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/hep.27085","article-title":"Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2","volume":"60","author":"Liu","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib110","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/hep.27592","article-title":"Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression","volume":"61","author":"Nagahashi","year":"2015","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib111","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1194\/jlr.R069286","article-title":"The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases","volume":"57","author":"Nagahashi","year":"2016","journal-title":"J Lipid Res"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100120_bib112","doi-asserted-by":"crossref","first-page":"12058","DOI":"10.1074\/jbc.M609559200","article-title":"Sphingosine kinase type 2 activation by ERK-mediated phosphorylation","volume":"282","author":"Hait","year":"2007","journal-title":"J Biol Chem"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100120_bib113","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1073\/pnas.1903316116","article-title":"MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus","volume":"116","author":"Meixiong","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib114","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1055\/s-0041-1730923","article-title":"MRGPRX4 in cholestatic pruritus","volume":"41","author":"Yu","year":"2021","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib116","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2796.2006.01731.x","article-title":"Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man","volume":"260","author":"Lund\u00e5sen","year":"2006","journal-title":"J Intern Med"},{"issue":"6024","key":"10.1016\/j.pharmr.2026.100120_bib117","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","article-title":"FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis","volume":"331","author":"Kir","year":"2011","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib118","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s42255-019-0074-3","article-title":"Metabolic Messengers: fibroblast growth factor 15\/19","volume":"1","author":"Gadaleta","year":"2019","journal-title":"Nat Metab"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib119","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2009.08.001","article-title":"TGR5-mediated bile acid sensing controls glucose homeostasis","volume":"10","author":"Thomas","year":"2009","journal-title":"Cell Metab"},{"issue":"7075","key":"10.1016\/j.pharmr.2026.100120_bib120","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature04330","article-title":"Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation","volume":"439","author":"Watanabe","year":"2006","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib121","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nchembio.1864","article-title":"A biosynthetic pathway for a prominent class of microbiota-derived bile acids","volume":"11","author":"Devlin","year":"2015","journal-title":"Nat Chem Biol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib122","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MOG.0000000000000057","article-title":"Bile acids and the gut microbiome","volume":"30","author":"Ridlon","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib123","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cld.861","article-title":"Bile acid biology, pathophysiology, and therapeutics","volume":"15","author":"Chiang","year":"2020","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib124","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","article-title":"Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis","volume":"15","author":"Jia","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108142","article-title":"Infection with Bacteroides Phage BV01 alters the host transcriptome and bile acid metabolism in a common human gut microbe","volume":"32","author":"Campbell","year":"2020","journal-title":"Cell Rep"},{"issue":"7785","key":"10.1016\/j.pharmr.2026.100120_bib126","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile acid metabolites control TH17 and Treg cell differentiation","volume":"576","author":"Hang","year":"2019","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib127","first-page":"1467","article-title":"Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor","volume":"29","author":"Staudinger","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib128","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3109\/03602532.2012.748793","article-title":"Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver","volume":"45","author":"Staudinger","year":"2013","journal-title":"Drug Metab Rev"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MOG.0000000000000156","article-title":"Bile acids as metabolic regulators","volume":"31","author":"Li","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib130","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1124\/pharmrev.124.000978","article-title":"Bile acid signaling in metabolic and inflammatory diseases and drug development","volume":"76","author":"Li","year":"2024","journal-title":"Pharmacol Rev"},{"issue":"25","key":"10.1016\/j.pharmr.2026.100120_bib131","doi-asserted-by":"crossref","first-page":"7164","DOI":"10.1016\/j.cell.2024.10.001","article-title":"Structure-guided discovery of bile acid derivatives for treating liver diseases without causing itch","volume":"187","author":"Yang","year":"2024","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib132","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s11427-023-2353-0","article-title":"Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis","volume":"67","author":"Jia","year":"2024","journal-title":"Sci China Life Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib133","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile acids as hormones: the FXR-FGF15\/19 pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib134","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.apsb.2023.11.011","article-title":"Mechanism of action of the bile acid receptor TGR5 in obesity","volume":"14","author":"Lun","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib135","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.molmet.2017.03.006","article-title":"Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway","volume":"6","author":"Yusta","year":"2017","journal-title":"Mol Metab"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib136","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cmet.2011.11.006","article-title":"TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading","volume":"14","author":"Pols","year":"2011","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib137","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib138","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","article-title":"Modulation of the fecal bile acid profile by gut microbiota in cirrhosis","volume":"58","author":"Kakiyama","year":"2013","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib139","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/j.2040-4603.2022.tb00205.x","article-title":"Bile acids, gut microbiome and the road to fatty liver disease","volume":"12","author":"Hylemon","year":"2021","journal-title":"Compr Physiol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib140","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1515\/mr-2024-0020","article-title":"Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases","volume":"4","author":"Wang","year":"2024","journal-title":"Med Rev (2021)"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib141","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib142","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1097\/HEP.0000000000000706","article-title":"From NAFLD to MASLD: promise and pitfalls of a new definition","volume":"79","author":"Cusi","year":"2024","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib143","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.jhep.2024.02.010","article-title":"Changing from NAFLD to MASLD: the implications for health-related quality of life data","volume":"80","author":"Hashida","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib144","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70127","article-title":"The global burden of MASLD in the past three decades","volume":"45","author":"Paik","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.pharmr.2026.100120_bib145","article-title":"From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients","volume":"15","author":"Huang","year":"2024","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib146","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease","volume":"69","author":"Ponziani","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib147","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","article-title":"Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib148","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib149","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib150","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1499-3872(17)60019-5","article-title":"Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease","volume":"16","author":"Shen","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib151","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41467-019-09455-9","article-title":"A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease","volume":"10","author":"Caussy","year":"2019","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib152","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/jgh.16147","article-title":"A metagenomic study identifies a Prevotella copri enriched microbial profile associated with non-alcoholic steatohepatitis in subjects with obesity","volume":"38","author":"Moran-Ramos","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib153","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1053\/j.gastro.2019.06.028","article-title":"Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease","volume":"157","author":"Schwimmer","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib154","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3390\/nu12030820","article-title":"Gut microbiota dysbiosis in patients with biopsy-proven nonalcoholic fatty liver disease: a cross-sectional study in Taiwan","volume":"12","author":"Tsai","year":"2020","journal-title":"Nutrients"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100120_bib155","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.3390\/nu15132923","article-title":"Marine chitosan-oligosaccharide ameliorated plasma cholesterol in hypercholesterolemic hamsters by modifying the gut microflora, bile acids, and short-chain fatty acids","volume":"15","author":"Abdo","year":"2023","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib156","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/hep.28572","article-title":"Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach","volume":"65","author":"Del Chierico","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib157","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00535-023-02075-7","article-title":"Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism","volume":"59","author":"Cornejo-Pareja","year":"2024","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib158","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib159","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib160","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/hep.32197","article-title":"Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease","volume":"75","author":"Kwan","year":"2022","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib161","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.cgh.2013.02.015","article-title":"Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease","volume":"11","author":"Raman","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2026.100120_bib162","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1279354","article-title":"Increased fecal ethanol and enriched ethanol-producing gut bacteria Limosilactobacillus fermentum, Enterocloster bolteae, Mediterraneibacter gnavus and Streptococcus mutans in nonalcoholic steatohepatitis","volume":"13","author":"Mbaye","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib163","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","article-title":"A universal gut-microbiome-derived signature predicts cirrhosis","volume":"32","author":"Oh","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2026.100120_bib164","doi-asserted-by":"crossref","first-page":"8096","DOI":"10.1038\/srep08096","article-title":"Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease","volume":"5","author":"Jiang","year":"2015","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib165","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.3390\/ijms25073640","article-title":"The reduced gut Lachnospira species is linked to liver enzyme elevation and insulin resistance in pediatric fatty liver disease","volume":"25","author":"Tsai","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100120_bib166","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1177\/2050640618804444","article-title":"Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease","volume":"6","author":"Rau","year":"2018","journal-title":"U Eur Gastroenterol J"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib167","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","article-title":"Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women","volume":"24","author":"Hoyles","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100120_bib168","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001033","article-title":"Characterization of gut microbiome in liver transplant recipients with nonalcoholic steatohepatitis","volume":"6","author":"Satapathy","year":"2020","journal-title":"Transplant Direct"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib169","article-title":"Altered gut microbial profile accompanied by abnormal short chain fatty acid metabolism exacerbates nonalcoholic fatty liver disease progression","volume":"14","author":"Yang","year":"2024","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100120_bib170","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/s41591-022-02016-6","article-title":"Microbiome-derived ethanol in nonalcoholic fatty liver disease","volume":"28","author":"Meijnikman","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib171","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cmet.2019.08.018","article-title":"Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae","volume":"30","author":"Yuan","year":"2019","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib172","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ajcn\/nqac074","article-title":"Gut microbiota-derived metabolite trimethylamine-N-oxide and multiple health outcomes: an umbrella review and updated meta-analysis","volume":"116","author":"Li","year":"2022","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib173","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2010.11.049","article-title":"Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency","volume":"140","author":"Spencer","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2026.100120_bib174","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1380476","article-title":"The potential of short-chain fatty acid epigenetic regulation in chronic low-grade inflammation and obesity","volume":"15","author":"Kopczy\u0144ska","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharmr.2026.100120_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103202","article-title":"A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis","volume":"63","author":"Pan","year":"2021","journal-title":"EBiomedicine"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib176","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2337\/db11-1019","article-title":"Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2","volume":"61","author":"Tolhurst","year":"2012","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib177","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.cmet.2015.09.028","article-title":"Microbiota-dependent hepatic lipogenesis mediated by stearoyl CoA desaturase 1 (SCD1) promotes metabolic syndrome in TLR5-deficient mice","volume":"22","author":"Singh","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2026.100120_bib178","doi-asserted-by":"crossref","DOI":"10.1007\/s12602-025-10761-6","article-title":"Probiotic-derived strain-specific metabolites ameliorate metabolic dysfunction-associated steatotic liver disease through modulation of the gut-liver axis","author":"Yoon","year":"2025","journal-title":"Probiotics Antimicrob Proteins"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib179","doi-asserted-by":"crossref","first-page":"E532","DOI":"10.1152\/ajpendo.00258.2011","article-title":"Cytochrome P-450 CYP2E1 knockout mice are protected against high-fat diet-induced obesity and insulin resistance","volume":"302","author":"Zong","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100120_bib180","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201900257","article-title":"Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease","volume":"63","author":"Tan","year":"2019","journal-title":"Mol Nutr Food Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib181","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nm.3145","article-title":"Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis","volume":"19","author":"Koeth","year":"2013","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100120_bib182","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.3748\/wjg.v25.i20.2450","article-title":"Trimethylamine N-oxide attenuates high-fat high-cholesterol diet-induced steatohepatitis by reducing hepatic cholesterol overload in rats","volume":"25","author":"Zhao","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"B","key":"10.1016\/j.pharmr.2026.100120_bib183","article-title":"Gut microbiota metabolite trimethylamine N-oxide promoted NAFLD progression by exacerbating intestinal barrier disruption and intrahepatic cellular imbalance","volume":"142","author":"Nian","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib184","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jceh.2022.01.006","article-title":"Demonstration of gut-barrier dysfunction in early stages of non-alcoholic fatty liver disease: a proof-of-concept study","volume":"12","author":"Kaushal","year":"2022","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib185","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib186","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.chom.2015.03.005","article-title":"Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function","volume":"17","author":"Kelly","year":"2015","journal-title":"Cell Host Microbe"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib187","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11605-021-05188-7","article-title":"The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases","volume":"26","author":"An","year":"2022","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.pharmr.2026.100120_bib188","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1038\/ncomms7734","article-title":"Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome","volume":"6","author":"Macia","year":"2015","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib189","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100120_bib190","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib191","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151829","article-title":"Bile acids and dysbiosis in non-alcoholic fatty liver disease","volume":"11","author":"Mouzaki","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib192","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib193","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3390\/biom13091356","article-title":"Alterations in circulating bile acids in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis","volume":"13","author":"Lai","year":"2023","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib194","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/gutjnl-2018-316307","article-title":"Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease","volume":"68","author":"Chu","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.pharmr.2026.100120_bib195","article-title":"Bile acid signaling in MASLD: from pathogenesis to therapeutic applications","volume":"19","author":"Simbrunner","year":"2025","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib196","doi-asserted-by":"crossref","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"Chiang","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.pharmr.2026.100120_bib197","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116658","article-title":"A Current Understanding of FXR in NAFLD: the multifaceted regulatory role of FXR and novel lead discovery for drug development","volume":"175","author":"Tang","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib198","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","article-title":"An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease","volume":"151","author":"Gonzalez","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2026.100120_bib199","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat Commun"},{"issue":"4 Pt B","key":"10.1016\/j.pharmr.2026.100120_bib200","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bbadis.2017.09.019","article-title":"Nuclear receptor FXR, bile acids and liver damage: introducing the progressive familial intrahepatic cholestasis with FXR mutations","volume":"1864","author":"Cariello","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib201","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib202","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.cmet.2020.11.017","article-title":"Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism","volume":"33","author":"Zheng","year":"2021","journal-title":"Cell Metab"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib203","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100120_bib204","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202410602","article-title":"Conjugated lithocholic acid activates hepatic TGR5 to promote lipotoxicity and MASLD-MASH transition by disrupting carnitine biosynthesis","volume":"12","author":"Lian","year":"2025","journal-title":"Adv Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib205","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jso.25629","article-title":"Association of preoperative monocyte-to-lymphocyte and neutrophil-to-lymphocyte ratio with recurrence-free and overall survival after resection of pancreatic neuroendocrine tumors (US-NETSG)","volume":"120","author":"Panni","year":"2019","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib206","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12964-025-02249-1","article-title":"Conjugated bile acids promote metabolic dysfunction-associated steatotic liver disease through inducing nuclear translocation of sphingosine-1-phosphate receptor 2 to disrupt peroxisome proliferator-activated receptor alpha","volume":"23","author":"Miao","year":"2025","journal-title":"Cell Commun Signal"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib207","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1128\/AEM.65.7.3158-3163.1999","article-title":"Formation of hyodeoxycholic acid from muricholic acid and hyocholic acid by an unidentified gram-positive rod termed HDCA-1 isolated from rat intestinal microflora","volume":"65","author":"Eyssen","year":"1999","journal-title":"Appl Environ Microbiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib208","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FPC.0000000000000489","article-title":"Pregnane X receptor gene variant rs7643645 and total mortality in subjects with nonalcoholic fatty liver disease","volume":"33","author":"K\u00e4r\u00e4j\u00e4m\u00e4ki","year":"2023","journal-title":"Pharmacogenet Genomics"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib209","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41575-025-01084-6","article-title":"Public health policies to prevent alcohol-related liver disease","volume":"22","author":"Parker","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2026.100120_bib210","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-pathmechdis-031521-030435","article-title":"Recent advances in understanding of pathogenesis of alcohol-associated liver disease","volume":"18","author":"Wu","year":"2023","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib211","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41575-018-0099-1","article-title":"Alcohol, liver disease and the gut microbiota","volume":"16","author":"Bajaj","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib212","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","article-title":"Alcoholic liver disease","volume":"4","author":"Seitz","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib213","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/hep.31178","article-title":"Fecal microbiome distinguishes alcohol consumption from alcoholic hepatitis but does not discriminate disease severity","volume":"72","author":"Smirnova","year":"2020","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib214","doi-asserted-by":"crossref","first-page":"G966","DOI":"10.1152\/ajpgi.00380.2011","article-title":"Colonic microbiome is altered in alcoholism","volume":"302","author":"Mutlu","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib215","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2015-310585","article-title":"Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease","volume":"65","author":"Llopis","year":"2016","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib216","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40168-017-0359-2","article-title":"Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease","volume":"5","author":"Dubinkina","year":"2017","journal-title":"Microbiome"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib217","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/gutjnl-2016-313432","article-title":"Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease","volume":"67","author":"Grander","year":"2018","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib218","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/apt.14949","article-title":"Bile acid homeostasis and intestinal dysbiosis in alcoholic hepatitis","volume":"48","author":"Ciocan","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib219","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/hep.29623","article-title":"The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"issue":"7783","key":"10.1016\/j.pharmr.2026.100120_bib220","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","article-title":"Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease","volume":"575","author":"Duan","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib221","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/liv.14383","article-title":"Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease","volume":"40","author":"Addolorato","year":"2020","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib222","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2020.1785251","article-title":"Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients","volume":"12","author":"Lang","year":"2020","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib223","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2021.1946367","article-title":"Decrease in acetyl-CoA pathway utilizing butyrate-producing bacteria is a key pathogenic feature of alcohol-induced functional gut microbial dysbiosis and development of liver disease in mice","volume":"13","author":"Singhal","year":"2021","journal-title":"Gut Microbes"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib224","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3390\/ijms24032461","article-title":"Microbiome alterations in alcohol use disorder and alcoholic liver disease","volume":"24","author":"Litwinowicz","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib225","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s12072-023-10518-9","article-title":"Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease","volume":"18","author":"Ganesan","year":"2024","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib226","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41522-024-00602-9","article-title":"Minibioreactor arrays to model microbiome response to alcohol and tryptophan in the context of alcohol-associated liver disease","volume":"10","author":"Hu","year":"2024","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib227","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.chom.2024.06.008","article-title":"Dietary fiber alleviates alcoholic liver injury via Bacteroides acidifaciens and subsequent ammonia detoxification","volume":"32","author":"Shen","year":"2024","journal-title":"Cell Host Microbe"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib228","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.chom.2025.05.003","article-title":"Targeted inhibition of pathobiont virulence factor mitigates alcohol-associated liver disease","volume":"33","author":"Yang","year":"2025","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib229","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2517821","article-title":"Lachnospiraceae bacterium alleviates alcohol-associated liver disease by enhancing N-acetyl-glutamic acid levels and inhibiting ferroptosis through the KEAP1-NRF2 pathway","volume":"17","author":"Zhang","year":"2025","journal-title":"Gut Microbes"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib230","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jhep.2019.09.029","article-title":"The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease","volume":"72","author":"Chu","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib231","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1172\/JCI90562","article-title":"Intestinal fungi contribute to development of alcoholic liver disease","volume":"127","author":"Yang","year":"2017","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib232","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.30832","article-title":"Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis","volume":"71","author":"Lang","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2026.100120_bib233","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.699253","article-title":"Dynamic changes of the fungal microbiome in alcohol use disorder","volume":"12","author":"Hartmann","year":"2021","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib234","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2307586","article-title":"Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease","volume":"16","author":"Viebahn","year":"2024","journal-title":"Gut Microbes"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib235","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/hep.31459","article-title":"Intestinal virome in patients with alcoholic hepatitis","volume":"72","author":"Jiang","year":"2020","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib236","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/hep4.1947","article-title":"Intestinal virome in patients with alcohol use disorder and after abstinence","volume":"6","author":"Hsu","year":"2022","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib237","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1097\/HEP.0000000000000238","article-title":"Any alcohol use in NAFLD patients is associated with significant changes to the intestinal virome","volume":"77","author":"Hsu","year":"2023","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100120_bib238","doi-asserted-by":"crossref","DOI":"10.1172\/JCI188541","article-title":"Activation of intestinal endogenous retroviruses by alcohol exacerbates liver disease","volume":"135","author":"Cabr\u00e9","year":"2025","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib239","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.gastro.2014.09.014","article-title":"Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice","volume":"148","author":"Chen","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib240","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jhep.2018.03.031","article-title":"Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis","volume":"69","author":"Brandl","year":"2018","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib241","doi-asserted-by":"crossref","first-page":"G929","DOI":"10.1152\/ajpgi.00315.2013","article-title":"Colonic inflammation and secondary bile acids in alcoholic cirrhosis","volume":"306","author":"Kakiyama","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib242","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/hep4.1671","article-title":"Metabolic profiling of bile acids in the urine of patients with alcohol-associated liver disease","volume":"5","author":"He","year":"2021","journal-title":"Hepatol Commun"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100120_bib243","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113860","article-title":"Serum metabolomic profiling in acute alcoholic hepatitis identifies multiple dysregulated pathways","volume":"9","author":"Rachakonda","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib244","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/alcalc\/agaa005","article-title":"Chronic alcohol consumption increased bile acid levels in enterohepatic circulation and reduced efficacy of irinotecan","volume":"55","author":"Gong","year":"2020","journal-title":"Alcohol Alcohol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib245","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/hep4.1885","article-title":"Development of alcohol-associated hepatitis is associated with specific changes in gut-modified bile acids","volume":"6","author":"Muthiah","year":"2022","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib246","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2382767","article-title":"Serum bile acids profiles are altered without change of the gut microbiota composition following a seven-day prednisolone therapy in severe alcoholic hepatitis","volume":"16","author":"Esparteiro","year":"2024","journal-title":"Gut Microbes"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100120_bib247","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110940","article-title":"Elevated systemic total bile acids escalate susceptibility to alcohol-associated liver disease","volume":"27","author":"Paudel","year":"2024","journal-title":"iScience"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib248","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70128","article-title":"Serum metabolite profile in progressive versus nonprogressive alcohol-related liver disease: a cross-sectional metabolomics study","volume":"45","author":"Puhakka","year":"2025","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib249","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41575-023-00766-3","article-title":"Paracellular permeability and tight junction regulation in gut health and disease","volume":"20","author":"Horowitz","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib250","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110937","article-title":"TRPV6 channel mediates alcohol-induced gut barrier dysfunction and systemic response","volume":"39","author":"Meena","year":"2022","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib251","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/nure.12027","article-title":"Ethanol metabolism and its effects on the intestinal epithelial barrier","volume":"71","author":"Elamin","year":"2013","journal-title":"Nutr Rev"},{"issue":"7687","key":"10.1016\/j.pharmr.2026.100120_bib252","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nature25154","article-title":"Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells","volume":"553","author":"Garaycoechea","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib253","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jhep.2018.05.021","article-title":"Intestinal HIF-1alpha deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction","volume":"69","author":"Shao","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib254","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053028","article-title":"Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment","volume":"8","author":"Bull-Otterson","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib255","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1016\/j.ajpath.2011.08.039","article-title":"Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury","volume":"179","author":"Wang","year":"2011","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib256","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.26321","article-title":"Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice","volume":"58","author":"Hartmann","year":"2013","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib257","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.chom.2016.01.003","article-title":"Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation","volume":"19","author":"Wang","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib258","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/gutjnl-2018-317232","article-title":"Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice","volume":"68","author":"Hendrikx","year":"2019","journal-title":"Gut"},{"issue":"42","key":"10.1016\/j.pharmr.2026.100120_bib259","doi-asserted-by":"crossref","first-page":"E4485","DOI":"10.1073\/pnas.1415174111","article-title":"Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity","volume":"111","author":"Leclercq","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib260","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.27779","article-title":"Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis","volume":"62","author":"Michelena","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib261","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/hep.28456","article-title":"Interleukin-1 and inflammasomes in alcoholic liver disease\/acute alcoholic hepatitis and nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"64","author":"Tilg","year":"2016","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100120_bib262","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/s41423-025-01291-w","article-title":"Immunological mechanisms and emerging therapeutic targets in alcohol-associated liver disease","volume":"22","author":"Shen","year":"2025","journal-title":"Cell Mol Immunol"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100120_bib263","doi-asserted-by":"crossref","first-page":"5762","DOI":"10.7150\/ijbs.121255","article-title":"Neutrophil recruitment via hepatocyte IL-1alpha drives NETs-mediated AIM2 hepatocyte apoptosis in alcohol-associated steatohepatitis","volume":"21","author":"Zhang","year":"2025","journal-title":"Int J Biol Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib264","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.chom.2023.02.001","article-title":"Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease","volume":"31","author":"Zeng","year":"2023","journal-title":"Cell Host Microbe"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib265","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1136\/gutjnl-2024-334412","article-title":"Opposite regulation of intestinal and intrahepatic CD8+ T cells controls alcohol-associated liver disease progression","volume":"74","author":"Maccioni","year":"2025","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib266","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/HEP.0000000000000019","article-title":"Conventional type 1 dendritic cells protect against gut barrier disruption via maintaining Akkermansia muciniphila in alcoholic steatohepatitis","volume":"78","author":"Hao","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib267","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2020.1851986","article-title":"The role of gut vascular barrier in experimental alcoholic liver disease and A. muciniphila supplementation","volume":"12","author":"Grander","year":"2020","journal-title":"Gut Microbes"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib268","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3390\/cells11060968","article-title":"Modulation of the bile acid enterohepatic cycle by intestinal microbiota alleviates alcohol liver disease","volume":"11","author":"Ciocan","year":"2022","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib269","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/hep.29676","article-title":"Modulation of the intestinal bile acid\/farnesoid X receptor\/fibroblast growth factor 15 axis improves alcoholic liver disease in mice","volume":"67","author":"Hartmann","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib270","article-title":"Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis","volume":"3","author":"Spatz","year":"2021","journal-title":"JHEP Rep"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib271","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/hep.32608","article-title":"Probiotic-derived nanoparticles inhibit ALD through intestinal miR194 suppression and subsequent FXR activation","volume":"77","author":"Jiang","year":"2023","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib272","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s42255-024-01063-2","article-title":"Coordinated action of a gut-liver pathway drives alcohol detoxification and consumption","volume":"6","author":"Fu","year":"2024","journal-title":"Nat Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib273","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/0016-5085(95)90027-6","article-title":"Antibiotics prevent liver injury in rats following long-term exposure to ethanol","volume":"108","author":"Adachi","year":"1995","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib274","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jhep.2016.11.008","article-title":"Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice","volume":"66","author":"Ferrere","year":"2017","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib275","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202405781","article-title":"Postbiotics from Lactobacillus johnsonii activates gut innate immunity to mitigate alcohol-associated liver disease","volume":"12","author":"Yin","year":"2025","journal-title":"Adv Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib276","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3350\/cmh.2020.0057","article-title":"Fecal microbiota transplantation in alcohol related liver diseases","volume":"26","author":"Shasthry","year":"2020","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib277","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.31496","article-title":"A randomized clinical trial of fecal microbiota transplant for alcohol use disorder","volume":"73","author":"Bajaj","year":"2021","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100120_bib278","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.3390\/jcm14175981","article-title":"Fecal microbiota transplantation in patients with alcohol-associated cirrhosis: a clinical trial","volume":"14","author":"Ichim","year":"2025","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib279","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/HEP.0000000000000645","article-title":"New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease","volume":"82","author":"Diaz","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2026.100120_bib280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.698900","article-title":"Association of gut microbiota and metabolites with disease progression in children with biliary atresia","volume":"12","author":"Song","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib281","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.21111","article-title":"Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study","volume":"43","author":"Ropponen","year":"2006","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib282","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/HEP.0000000000001093","article-title":"Central role for cholangiocyte pathobiology in cholestatic liver diseases","volume":"82","author":"Jalan-Sakrikar","year":"2025","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib283","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/ncpgasthep1179","article-title":"Mechanisms of disease: inborn errors of bile acid synthesis","volume":"5","author":"Sundaram","year":"2008","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib284","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41572-025-00600-x","article-title":"Primary sclerosing cholangitis","volume":"11","author":"Manns","year":"2025","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib285","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/hepr.13509","article-title":"Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis","volume":"50","author":"Furukawa","year":"2020","journal-title":"Hepatol Res"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib286","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","article-title":"The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls","volume":"66","author":"Kummen","year":"2017","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib287","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/gutjnl-2020-323565","article-title":"Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis","volume":"71","author":"Liu","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib288","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s10020-024-00830-x","article-title":"The gut microbiota-bile acid axis in cholestatic liver disease","volume":"30","author":"Sun","year":"2024","journal-title":"Mol Med"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib289","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/jgh.14777","article-title":"Gut microbial profile in biliary atresia: a case-control study","volume":"35","author":"Wang","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2026.100120_bib290","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.914247","article-title":"Comprehensive analysis of gut microbiota and fecal bile acid profiles in children with biliary atresia","volume":"12","author":"Yang","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib291","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41575-022-00690-y","article-title":"The microbiota and the gut-liver axis in primary sclerosing cholangitis","volume":"20","author":"Hov","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib292","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib293","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1007\/s11033-021-06567-8","article-title":"Characterization of the gut microbiota in patients with primary sclerosing cholangitis compared to inflammatory bowel disease and healthy controls","volume":"48","author":"Ostadmohammadi","year":"2021","journal-title":"Mol Biol Rep"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib294","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13714","article-title":"Alterations in gut microbiota and elevated serum bilirubin in primary biliary cholangitis patients treated with ursodeoxycholic acid","volume":"52","author":"Han","year":"2022","journal-title":"Eur J Clin Investig"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib295","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/liv.14153","article-title":"The gut microbial influence on cholestatic liver disease","volume":"39","author":"Kummen","year":"2019","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib296","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jhep.2016.09.020","article-title":"The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation","volume":"66","author":"Schrumpf","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib297","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.27927","article-title":"Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis","volume":"63","author":"Tabibian","year":"2016","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib298","doi-asserted-by":"crossref","DOI":"10.1099\/mic.0.001608","article-title":"The interaction between IL-17 and gut microbiota contributes to cholestatic liver disease in children","volume":"171","author":"He","year":"2025","journal-title":"Microbiology"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib299","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1053\/j.gastro.2018.02.019","article-title":"Alterations in intestinal microbiota lead to production of interleukin 17 by intrahepatic \u03b3\u03b4 T-cell receptor-positive cells and pathogenesis of cholestatic liver disease","volume":"154","author":"Tedesco","year":"2018","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100120_bib300","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v31.i10.101014","article-title":"Lactococcus garvieae aggravates cholestatic liver disease by increasing intestinal permeability and enhancing bile acid reabsorption","volume":"31","author":"Liu","year":"2025","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib301","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat Microbiol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib302","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s10620-006-9544-z","article-title":"Abnormal intestinal permeability in primary biliary cirrhosis","volume":"51","author":"Feld","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib303","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41467-023-36981-4","article-title":"Gut microbiota alters host bile acid metabolism to contribute to intrahepatic cholestasis of pregnancy","volume":"14","author":"Tang","year":"2023","journal-title":"Nat Commun"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100120_bib304","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1042\/CS20230812","article-title":"Gut microbiota depletion aggravates bile acid-induced liver pathology in mice with a human-like bile acid composition","volume":"137","author":"Verkade","year":"2023","journal-title":"Clin Sci"},{"issue":"25","key":"10.1016\/j.pharmr.2026.100120_bib305","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.3748\/wjg.v23.i25.4548","article-title":"Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis","volume":"23","author":"Bajer","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib306","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1053\/j.gastro.2024.05.014","article-title":"Gut microbiota-derived butyrate induces epigenetic and metabolic reprogramming in myeloid-derived suppressor cells to alleviate primary biliary cholangitis","volume":"167","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib307","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1053\/j.gastro.2020.12.058","article-title":"Altered gut microbial metabolism of essential nutrients in primary sclerosing cholangitis","volume":"160","author":"Kummen","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib308","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/hep.1840060324","article-title":"The fasting B6 vitamer profile and response to a pyridoxine load in normal and cirrhotic subjects","volume":"6","author":"Henderson","year":"1986","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2026.100120_bib309","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-230X-5-11","article-title":"The relation between plasma tyrosine concentration and fatigue in primary biliary cirrhosis and primary sclerosing cholangitis","volume":"5","author":"ter Borg","year":"2005","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib310","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.dld.2011.10.025","article-title":"Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study","volume":"44","author":"Trottier","year":"2012","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib311","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12016-019-08731-2","article-title":"Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis","volume":"58","author":"Chen","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib312","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000452","article-title":"Unique bile acid profiles in the bile ducts of patients with primary sclerosing cholangitis","volume":"8","author":"Kayashima","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.pharmr.2026.100120_bib313","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/CEG.S186097","article-title":"A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis","volume":"12","author":"Vaughn","year":"2019","journal-title":"Clin Exp Gastroenterol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib314","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/2050640617708953","article-title":"The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease","volume":"6","author":"Torres","year":"2018","journal-title":"U Eur Gastroenterol J"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib315","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000382","article-title":"Rapid in vivo evaluation system for cholestasis-related genes in mice with humanized bile acid profiles","volume":"8","author":"Wakasa","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.pharmr.2026.100120_bib316","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.aca.2020.07.067","article-title":"Global profiling and identification of bile acids by multi-dimensional data mining to reveal a way of eliminating abnormal bile acids","volume":"1132","author":"Lin","year":"2020","journal-title":"Anal Chim Acta"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib317","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3390\/cells10081846","article-title":"Farnesoid X receptor as target for therapies to treat cholestasis-induced liver injury","volume":"10","author":"Petrescu","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib318","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajpath.2014.10.009","article-title":"The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats","volume":"185","author":"Verbeke","year":"2015","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib319","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03150-24","article-title":"Activation of gut FXR improves the metabolism of bile acids, intestinal barrier, and microbiota under cholestatic condition caused by GCDCA in mice","volume":"13","author":"Xie","year":"2025","journal-title":"Microbiol Spectr"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib320","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2015.12.010","article-title":"Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats","volume":"64","author":"\u00dabeda","year":"2016","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib321","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/liv.14906","article-title":"A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut-liver axis","volume":"41","author":"Xiao","year":"2021","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib322","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166320","article-title":"Prevotella copri ameliorates cholestasis and liver fibrosis in primary sclerosing cholangitis by enhancing the FXR signalling pathway","volume":"1868","author":"Jiang","year":"2022","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib323","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s42255-021-00452-1","article-title":"Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling","volume":"3","author":"Schneider","year":"2021","journal-title":"Nat Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib324","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.27973","article-title":"Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice","volume":"63","author":"Miethke","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib325","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/hep.26463","article-title":"The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice","volume":"58","author":"P\u00e9an","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib326","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/intimm\/dxaa002","article-title":"Deficiency of TGR5 exacerbates immune-mediated cholestatic hepatic injury by stabilizing the beta-catenin destruction complex","volume":"32","author":"Rao","year":"2020","journal-title":"Int Immunol"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100120_bib327","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.21037\/atm-21-2631","article-title":"TGR5 protects against cholestatic liver disease via suppressing the NF-\u03baB pathway and activating the Nrf2\/HO-1 pathway","volume":"9","author":"Yang","year":"2021","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib328","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/gutjnl-2018-316975","article-title":"TGR5-dependent hepatoprotection through the regulation of biliary epithelium barrier function","volume":"69","author":"Merlen","year":"2020","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib329","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2015-309458","article-title":"TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro","volume":"65","author":"Reich","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.pharmr.2026.100120_bib330","article-title":"Therapeutic opportunities of GPBAR1 in cholestatic diseases","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib331","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/j.2040-4603.2013.tb00495.x","article-title":"Physiology of cholangiocytes","volume":"3","author":"Tabibian","year":"2013","journal-title":"Compr Physiol"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100120_bib332","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.3748\/wjg.v12.i22.3496","article-title":"Cholangiocyte anion exchange and biliary bicarbonate excretion","volume":"12","author":"Banales","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pharmr.2026.100120_bib333","doi-asserted-by":"crossref","DOI":"10.1038\/srep13320","article-title":"Bile acids induce hepatic differentiation of mesenchymal stem cells","volume":"5","author":"Sawitza","year":"2015","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib334","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.29076","article-title":"The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice","volume":"65","author":"Wang","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib335","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41419-023-05615-4","article-title":"Necroptosis of macrophage is a key pathological feature in biliary atresia via GDCA\/S1PR2\/ZBP1\/p-MLKL axis","volume":"14","author":"Yang","year":"2023","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib336","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/s41418-020-00668-w","article-title":"RIP1 kinase activity promotes steatohepatitis through mediating cell death and inflammation in macrophages","volume":"28","author":"Tao","year":"2021","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.pharmr.2026.100120_bib337","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3389\/fimmu.2020.01149","article-title":"Macrophage sphingosine 1-phosphate Receptor 2 blockade attenuates liver inflammation and fibrogenesis triggered by NLRP3 inflammasome","volume":"11","author":"Hou","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib338","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3350\/cmh.2022.0327","article-title":"Taurocholic acid promotes hepatic stellate cell activation via S1PR2\/p38 MAPK\/YAP signaling under cholestatic conditions","volume":"29","author":"Yang","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.pharmr.2026.100120_bib339","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.16744","article-title":"Reversal of cholestatic liver disease by the inhibition of sphingosine 1-phosphate receptor 2 signaling","volume":"12","author":"Cao","year":"2024","journal-title":"PeerJ"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100120_bib340","doi-asserted-by":"crossref","first-page":"13801","DOI":"10.1073\/pnas.212494599","article-title":"Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR)","volume":"99","author":"Sonoda","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib341","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.2741\/3893","article-title":"Nuclear receptors CAR and PXR; therapeutic targets for cholestatic liver disease","volume":"16","author":"Kakizaki","year":"2011","journal-title":"Front Biosci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib342","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1073\/pnas.0409794102","article-title":"Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury","volume":"102","author":"Stedman","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib343","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1208\/s12248-022-00719-9","article-title":"Significance of the vitamin D receptor on crosstalk with nuclear receptors and regulation of enzymes and transporters","volume":"24","author":"Noh","year":"2022","journal-title":"AAPS J"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib344","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41568-021-00383-9","article-title":"The immunological and metabolic landscape in primary and metastatic liver cancer","volume":"21","author":"Li","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib345","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41572-025-00620-7","article-title":"Hepatoblastoma","volume":"11","author":"Pio","year":"2025","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib346","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/gutjnl-2017-315084","article-title":"Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma","volume":"68","author":"Ren","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib347","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13073-020-00796-5","article-title":"Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma","volume":"12","author":"Huang","year":"2020","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib348","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib349","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004779","article-title":"Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"10","author":"Lee","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib350","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Song","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib351","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41564-024-01890-9","article-title":"Gut-liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice","volume":"10","author":"Wang","year":"2025","journal-title":"Nat Microbiol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib352","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2476561","article-title":"Dysregulation of gut microbiota stimulates NETs-driven HCC intrahepatic metastasis: therapeutic implications of healthy faecal microbiota transplantation","volume":"17","author":"Deng","year":"2025","journal-title":"Gut Microbes"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib353","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2015.10.008","article-title":"Microbiota studies in the bile duct strongly suggest a role for Helicobacter pylori in extrahepatic cholangiocarcinoma","volume":"22","author":"Avil\u00e9s-Jim\u00e9nez","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib354","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/hep.30852","article-title":"Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma","volume":"71","author":"Jia","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247798","article-title":"Characterization of biliary microbiota dysbiosis in extrahepatic cholangiocarcinoma","volume":"16","author":"Saab","year":"2021","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib356","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3390\/cancers14092120","article-title":"Potential role of inflammation-promoting biliary microbiome in primary sclerosing cholangitis and cholangiocarcinoma","volume":"14","author":"Miyabe","year":"2022","journal-title":"Cancers"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100120_bib357","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.3390\/cancers14215379","article-title":"Dysbiosis of the fecal and biliary microbiota in biliary tract cancer","volume":"14","author":"Ito","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib358","doi-asserted-by":"crossref","first-page":"8766","DOI":"10.1038\/s41598-022-12658-8","article-title":"Unveiling microbiome profiles in human inner body fluids and tumor tissues with pancreatic or biliary tract cancer","volume":"12","author":"Okuda","year":"2022","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib359","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167152","article-title":"Gut microbiota regulates the ALK5\/NOX1 axis by altering glutamine metabolism to inhibit ferroptosis of intrahepatic cholangiocarcinoma cells","volume":"1870","author":"Zhang","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib360","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2018.09.004","article-title":"Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer","volume":"175","author":"Singh","year":"2018","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib361","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib362","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma, review","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"6369","key":"10.1016\/j.pharmr.2026.100120_bib363","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1126\/science.aal5240","article-title":"Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer","volume":"358","author":"Bullman","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib364","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003069","article-title":"Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib365","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2022.2156255","article-title":"Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma","volume":"15","author":"Chai","year":"2023","journal-title":"Gut Microbes"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100120_bib366","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e39547","article-title":"Existence and distribution of the microbiome in tumour tissues of children with hepatoblastoma","volume":"10","author":"Cui","year":"2024","journal-title":"Heliyon"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib367","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/HEP.0000000000000427","article-title":"Intratumoral microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC","volume":"78","author":"Li","year":"2023","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib368","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.3390\/cancers13112648","article-title":"Association between pre-diagnostic serum bile acids and hepatocellular carcinoma: the Singapore Chinese health study","volume":"13","author":"Thomas","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib369","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100073","article-title":"Pathological and therapeutic roles of bile acid metabolism and signaling in hepatocellular carcinoma: insights from human and mouse studies","volume":"77","author":"Wang","year":"2025","journal-title":"Pharmacol Rev"},{"issue":"6730","key":"10.1016\/j.pharmr.2026.100120_bib370","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1126\/science.adl4100","article-title":"Bile acid synthesis impedes tumor-specific T cell responses during liver cancer","volume":"387","author":"Varanasi","year":"2025","journal-title":"Science"},{"issue":"Suppl","key":"10.1016\/j.pharmr.2026.100120_bib371","first-page":"77","article-title":"Identification of biliary bile acids in patients with benign biliary diseases, hepatocellular carcinoma and cholangiocarcinoma","volume":"13","author":"Jusakul","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib372","article-title":"Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma","volume":"8","author":"Song","year":"2018","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100120_bib373","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.3390\/ijms24108597","article-title":"Establishment and validation of a novel risk score for hepatocellular carcinoma based on bile acid and bile salt metabolism-related genes","volume":"24","author":"Shi","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib374","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12935-021-01871-6","article-title":"Identifying SLC27A5 as a potential prognostic marker of hepatocellular carcinoma by weighted gene co-expression network analysis and in vitro assays","volume":"21","author":"Zhang","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib375","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41418-019-0399-1","article-title":"SLC27A5 deficiency activates NRF2\/TXNRD1 pathway by increased lipid peroxidation in HCC","volume":"27","author":"Gao","year":"2020","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib376","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/path.5780","article-title":"Disordered farnesoid X receptor signaling is associated with liver carcinogenesis in Abcb11-deficient mice","volume":"255","author":"Wang","year":"2021","journal-title":"J Pathol"},{"key":"10.1016\/j.pharmr.2026.100120_bib377","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2147\/JHC.S392586","article-title":"The clinical relevance and immune correlation of SLC10 family genes in liver cancer","volume":"9","author":"Tian","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib378","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jhep.2014.06.008","article-title":"OATP1B3 expression is strongly associated with Wnt\/beta-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma","volume":"61","author":"Ueno","year":"2014","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib379","doi-asserted-by":"crossref","first-page":"801","DOI":"10.4161\/cbt.11.9.15176","article-title":"The analysis of organic anion transporting polypeptide (OATP) mRNA and protein patterns in primary and metastatic liver cancer","volume":"11","author":"Wlcek","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib380","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jhep.2020.07.036","article-title":"p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma","volume":"74","author":"Luo","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib381","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100120_bib382","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1158\/1535-7163.MCT-16-0153","article-title":"A novel small molecule activator of nuclear receptor SHP inhibits HCC cell migration via suppressing Ccl2","volume":"15","author":"Yang","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib383","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1053\/j.gastro.2008.01.006","article-title":"Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth","volume":"134","author":"He","year":"2008","journal-title":"Gastroenterology"},{"issue":"4 Pt B","key":"10.1016\/j.pharmr.2026.100120_bib384","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.bbadis.2017.08.016","article-title":"Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression","volume":"1864","author":"Erice","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib385","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.111855","article-title":"TGR5 promotes cholangiocarcinoma by interacting with mortalin","volume":"389","author":"Li","year":"2020","journal-title":"Exp Cell Res"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib386","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ccell.2025.05.017","article-title":"Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma","volume":"43","author":"Huang","year":"2025","journal-title":"Cancer Cell"},{"issue":"6391","key":"10.1016\/j.pharmr.2026.100120_bib387","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib388","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1039\/C8FO01143E","article-title":"Deoxycholic acid disrupts the intestinal mucosal barrier and promotes intestinal tumorigenesis","volume":"9","author":"Liu","year":"2018","journal-title":"Food Funct"},{"issue":"7456","key":"10.1016\/j.pharmr.2026.100120_bib389","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nature12347","article-title":"Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome","volume":"499","author":"Yoshimoto","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2026.100120_bib390","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106643","article-title":"Capsaicin shapes gut microbiota and pre-metastatic niche to facilitate cancer metastasis to liver","volume":"188","author":"Cheng","year":"2023","journal-title":"Pharmacol Res"},{"issue":"7854","key":"10.1016\/j.pharmr.2026.100120_bib391","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib392","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2410474","article-title":"Synergistic activity of Enterococcus Faecium-induced ferroptosis via expansion of IFN-\u03b3+CD8+ T cell population in advanced hepatocellular carcinoma treated with sorafenib","volume":"16","author":"Yu","year":"2024","journal-title":"Gut Microbes"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100120_bib393","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.cmet.2025.09.001","article-title":"Catenibacteriummitsuokai promotes hepatocellular carcinogenesis by binding to hepatocytes and generating quinolinic acid","volume":"37","author":"Zhang","year":"2025","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib394","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1038\/s41467-025-58809-z","article-title":"Disrupting bile acid metabolism by suppressing Fxr causes hepatocellular carcinoma induced by YAP activation","volume":"16","author":"Liu","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmr.2026.100120_bib395","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1756-8722-4-41","article-title":"Impact of bile acids on the growth of human cholangiocarcinoma via FXR","volume":"4","author":"Dai","year":"2011","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib396","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12911-023-02402-1","article-title":"Gut microbiome-based machine learning for diagnostic prediction of liver fibrosis and cirrhosis: a systematic review and meta-analysis","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Med Inform Decis Mak"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib397","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3390\/ijms26020527","article-title":"A systematic review of microbiota in cirrhosis: a change towards a more pathogenic predisposition","volume":"26","author":"Xirouchakis","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib398","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/acer.12704","article-title":"Alcoholic liver disease: the gut microbiome and liver cross talk","volume":"39","author":"Hartmann","year":"2015","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.pharmr.2026.100120_bib399","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120760","article-title":"Role of gut bacterial and non-bacterial microbiota in alcohol-associated liver disease: molecular mechanisms, biomarkers, and therapeutic prospective","volume":"305","author":"Zafari","year":"2022","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib400","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12876-025-03589-5","article-title":"Associations between changes in the gut microbiota and liver cirrhosis: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib401","article-title":"Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease","volume":"14","author":"Park","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib402","doi-asserted-by":"crossref","first-page":"32","DOI":"10.17998\/jlc.20.1.32","article-title":"Gut-microbiome taxonomic profiling as non-invasive biomarkers for the early detection of alcoholic hepatocellular carcinoma","volume":"20","author":"Seok","year":"2020","journal-title":"J Liver Cancer"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib403","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/jgh.15027","article-title":"Endogenous ethanol produced by intestinal bacteria induces mitochondrial dysfunction in non-alcoholic fatty liver disease","volume":"35","author":"Chen","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib404","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41575-025-01089-1","article-title":"Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma","volume":"22","author":"Lau","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib405","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41467-017-00796-x","article-title":"Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus","volume":"8","author":"Llorente","year":"2017","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib406","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/gb-2011-12-6-r60","article-title":"Metagenomic biomarker discovery and explanation","volume":"12","author":"Segata","year":"2011","journal-title":"Genome Biol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib407","doi-asserted-by":"crossref","DOI":"10.1128\/mSystems.00046-17","article-title":"Total lipopolysaccharide from the human gut microbiome silences toll-like receptor signaling","volume":"2","author":"d\u2019Hennezel","year":"2017","journal-title":"mSystems"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib408","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/1873-3468.14328","article-title":"Lipopolysaccharide and the gut microbiota: considering structural variation","volume":"596","author":"Mohr","year":"2022","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmr.2026.100120_bib409","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2025.1568672","article-title":"Enterotype-stratified gut microbial signatures in MASLD and cirrhosis based on integrated microbiome data","volume":"16","author":"Yuan","year":"2025","journal-title":"Front Microbiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib410","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1210\/clinem\/dgac659","article-title":"Circulating bile acids as biomarkers for disease diagnosis and prevention","volume":"108","author":"Qi","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib411","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1021\/acs.jproteome.5b00217","article-title":"Serum bile acids are associated with pathological progression of hepatitis B-induced cirrhosis","volume":"15","author":"Wang","year":"2016","journal-title":"J Proteome Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib412","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/liv.14453","article-title":"Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"40","author":"Adams","year":"2020","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib413","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4254\/wjh.v13.i4.433","article-title":"Bile acid indices as biomarkers for liver diseases I: diagnostic markers","volume":"13","author":"Alamoudi","year":"2021","journal-title":"World J Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib414","article-title":"NASH-related increases in plasma bile acid levels depend on insulin resistance","volume":"3","author":"Grzych","year":"2021","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib415","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/19490976.2015.1127483","article-title":"Consequences of bile salt biotransformations by intestinal bacteria","volume":"7","author":"Ridlon","year":"2016","journal-title":"Gut Microbes"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib416","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/hep.29561","article-title":"A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma","volume":"67","author":"Luo","year":"2018","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100120_bib417","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1002\/ijc.33051","article-title":"Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies","volume":"147","author":"Petrick","year":"2020","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib418","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/ijc.33236","article-title":"Metabolic perturbations prior to hepatocellular carcinoma diagnosis: findings from a prospective observational cohort study","volume":"148","author":"Stepien","year":"2021","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib419","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/ijc.33885","article-title":"Prediagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma","volume":"150","author":"Stepien","year":"2022","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100120_bib420","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.2337\/db13-0639","article-title":"Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids","volume":"62","author":"Haeusler","year":"2013","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib421","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib422","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/toxsci\/kfu228","article-title":"Urinary bile acids as biomarkers for liver diseases II. Signature profiles in patients","volume":"143","author":"Bathena","year":"2015","journal-title":"Toxicol Sci"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib423","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2337\/dc14-1239","article-title":"Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD","volume":"38","author":"Bazick","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2026.100120_bib424","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155666","article-title":"Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: results from a large multi-center study","volume":"147","author":"Kouvari","year":"2023","journal-title":"Metabolism"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100120_bib425","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.3748\/wjg.v30.i18.2440","article-title":"FibroScan-aspartate transaminase: a superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis","volume":"30","author":"Yin","year":"2024","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib426","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/s12072-025-10792-9","article-title":"A robust diagnostic model for high-risk MASH: integrating clinical parameters and circulating biomarkers through a multi-omics approach","volume":"19","author":"Zhang","year":"2025","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib427","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/HEP.0000000000000542","article-title":"Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis score (MASEF)","volume":"79","author":"Noureddin","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2026.100120_bib428","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156082","article-title":"Accurate non-invasive detection of MASH with fibrosis F2-F3 using a lightweight machine learning model with minimal clinical and metabolomic variables","volume":"163","author":"Stefanakis","year":"2025","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib429","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2026.100120_bib430","article-title":"The gut microbiota-bile acid axis: a potential therapeutic target for liver fibrosis","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib431","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut-liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib432","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib433","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrgastro.2015.94","article-title":"Inflammasome activation and function in liver disease","volume":"12","author":"Szabo","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib434","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1042\/CS20220697","article-title":"Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease","volume":"137","author":"Gillard","year":"2023","journal-title":"Clin Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib435","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s40168-023-01709-5","article-title":"Gut microbiota-bile acid crosstalk regulates murine lipid metabolism via the intestinal FXR-FGF19 axis in diet-induced humanized dyslipidemia","volume":"11","author":"Xu","year":"2023","journal-title":"Microbiome"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib436","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03303-24","article-title":"Insertion sequence-mediated phage resistance contributes to attenuated colonization of cytolytic Enterococcus faecalis variants in the gut","volume":"13","author":"Fujiki","year":"2025","journal-title":"Microbiol Spectr"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib437","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib438","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s12603-011-0357-1","article-title":"Probiotics in the gastrointestinal diseases of the elderly","volume":"16","author":"Malaguarnera","year":"2012","journal-title":"J Nutr Health Aging"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib439","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/microorganisms12030430","article-title":"Next-generation probiotics as novel therapeutics for improving human health: current trends and future perspectives","volume":"12","author":"Abouelela","year":"2024","journal-title":"Microorganisms"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100120_bib440","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1007\/s10620-019-05699-z","article-title":"Efficacy of probiotics and Synbiotics in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"64","author":"Liu","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib441","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3390\/nu16111668","article-title":"Implications of microbiota and immune system in development and progression of metabolic dysfunction-associated steatotic liver disease","volume":"16","author":"Popov","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmr.2026.100120_bib442","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.880014","article-title":"Effects of Synbiotics, probiotics, and prebiotics on liver enzymes of patients with non-alcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"9","author":"Kanchanasurakit","year":"2022","journal-title":"Front Nutr"},{"issue":"34","key":"10.1016\/j.pharmr.2026.100120_bib443","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo2794","article-title":"Inhibition of microbial deconjugation of micellar bile acids protects against intestinal permeability and liver injury","volume":"8","author":"Li","year":"2022","journal-title":"Sci Adv"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100120_bib444","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1111\/jgh.16256","article-title":"Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"38","author":"Rong","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib445","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12876-024-03356-y","article-title":"Efficacy of probiotics, prebiotics, and Synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Pan","year":"2024","journal-title":"BMC Gastroenterol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib446","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.alcohol.2008.08.006","article-title":"Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study","volume":"42","author":"Kirpich","year":"2008","journal-title":"Alcohol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib447","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/MEG.0000000000000458","article-title":"Effects of probiotics (cultured Lactobacillus subtilis\/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study","volume":"27","author":"Han","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib448","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/MEG.0b013e3282f5197e","article-title":"Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study","volume":"20","author":"Vleggaar","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib449","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2021.1946366","article-title":"Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary cholangitis","volume":"13","author":"Li","year":"2021","journal-title":"Gut Microbes"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib450","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5946\/ce.2015.117","article-title":"Fecal microbiota transplantation: current applications, effectiveness, and future perspectives","volume":"49","author":"Choi","year":"2016","journal-title":"Clin Endosc"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib451","first-page":"71","article-title":"Fecal microbiota transplantation: a comprehensive review","volume":"11","author":"Rai","year":"2024","journal-title":"Era\u2019s J Med Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib452","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2022.2038856","article-title":"The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases","volume":"14","author":"Ghani","year":"2022","journal-title":"Gut Microbes"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100120_bib453","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cgh.2011.08.014","article-title":"Treating Clostridium difficile infection with fecal microbiota transplantation","volume":"9","author":"Bakken","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib454","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ajg.2013.59","article-title":"Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis","volume":"108","author":"Kassam","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib455","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/M14-2693","article-title":"Fecal microbiota transplantation for Clostridium difficile infection: a systematic review","volume":"162","author":"Drekonja","year":"2015","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib456","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","article-title":"Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study","volume":"15","author":"Philips","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib457","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hep.29306","article-title":"Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial","volume":"66","author":"Bajaj","year":"2017","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib458","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial","volume":"115","author":"Craven","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pharmr.2026.100120_bib459","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.662159","article-title":"Effect of fecal microbiota transplantation combined with Mediterranean diet on insulin sensitivity in subjects with metabolic syndrome","volume":"12","author":"Koopen","year":"2021","journal-title":"Front Microbiol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib460","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib461","doi-asserted-by":"crossref","first-page":"65","DOI":"10.24017\/science.2024.2.6","article-title":"Fecal microbiota transplantation: a systematic review of therapeutic potential, preparation techniques, and delivery methods across medical conditions","volume":"9","author":"Qadir","year":"2024","journal-title":"KJAR"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib462","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"10215","key":"10.1016\/j.pharmr.2026.100120_bib463","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib464","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist Cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib465","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib466","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of Elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib467","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A Phase 3 trial of Seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2026.100120_bib468","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(25)00310-1","article-title":"LBO-001 Norucholic acid for the treatment of primary sclerosing cholangitis: 96-week analysis of a pivotal phase 3 trial","volume":"82","author":"Trauner","year":"2025","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100120_bib469","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep4.1244","article-title":"Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in Alagille syndrome","volume":"2","author":"Shneider","year":"2018","journal-title":"Hepatol Commun"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib470","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.4254\/wjh.v14.i9.1730","article-title":"Bile acids as drivers and biomarkers of hepatocellular carcinoma","volume":"14","author":"Colosimo","year":"2022","journal-title":"World J Hepatol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib471","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3892\/ijo.2022.5407","article-title":"Hepatocellular carcinoma: novel understandings and therapeutic strategies based on bile acids","volume":"61","author":"Luo","year":"2022","journal-title":"Int J Oncol"},{"issue":"6371","key":"10.1016\/j.pharmr.2026.100120_bib472","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib473","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib474","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/carcin\/bgl249","article-title":"Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice","volume":"28","author":"Kim","year":"2007","journal-title":"Carcinogenesis"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib475","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/gutjnl-2012-302945","article-title":"Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice","volume":"62","author":"Uriarte","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.pharmr.2026.100120_bib476","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114497","article-title":"Activation of FXR modulates SOCS3\/Jak2\/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model","volume":"186","author":"Attia","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib477","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2407-12-56","article-title":"Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma","volume":"12","author":"Miura","year":"2012","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib478","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036713","article-title":"Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models","volume":"7","author":"French","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2026.100120_bib479","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/164_2019_228","article-title":"Pharmacologic modulation of bile acid-FXR-FGF15\/FGF19 pathway for the treatment of nonalcoholic steatohepatitis","volume":"256","author":"Schumacher","year":"2019","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib480","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2026.100120_bib481","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2025.100399","article-title":"Berberine\u2019s impact on health: comprehensive biological, pharmacological, and nutritional perspectives","volume":"28","author":"Asghari","year":"2025","journal-title":"Metabol Open"},{"key":"10.1016\/j.pharmr.2026.100120_bib482","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.2147\/IDR.S431256","article-title":"Potentiation and mechanism of berberine as an antibiotic adjuvant against multidrug-resistant bacteria","volume":"16","author":"Zhou","year":"2023","journal-title":"Infect Drug Resist"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib483","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.7150\/ijbs.65476","article-title":"Berberine ameliorates DSS-induced intestinal mucosal barrier dysfunction through microbiota-dependence and Wnt\/beta-catenin pathway","volume":"18","author":"Dong","year":"2022","journal-title":"Int J Biol Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib484","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232630","article-title":"Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes","volume":"15","author":"Wang","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib485","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cells10020210","article-title":"Berberine prevents disease progression of nonalcoholic steatohepatitis through modulating multiple pathways","volume":"10","author":"Wang","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib486","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13578-024-01195-8","article-title":"Therapeutic potential of berberine in attenuating cholestatic liver injury: insights from a PSC mouse model","volume":"14","author":"Wang","year":"2024","journal-title":"Cell Biosci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib487","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/clpt.2012.237","article-title":"Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance","volume":"93","author":"Gonzalez de Castro","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100120_bib488","article-title":"Applications and challenges of biomarker-based predictive models in proactive health management","volume":"13","author":"Zhao","year":"2025","journal-title":"Front Public Health"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib489","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.14309\/ajg.0000000000000102","article-title":"Specific gut and salivary microbiota patterns are linked with different cognitive testing strategies in minimal hepatic encephalopathy","volume":"114","author":"Bajaj","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"7674","key":"10.1016\/j.pharmr.2026.100120_bib490","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature23889","article-title":"Strains, functions and dynamics in the expanded Human Microbiome Project","volume":"550","author":"Lloyd-Price","year":"2017","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100120_bib491","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41564-020-0743-8","article-title":"Genome-wide associations of human gut microbiome variation and implications for causal inference analyses","volume":"5","author":"Hughes","year":"2020","journal-title":"Nat Microbiol"},{"issue":"6285","key":"10.1016\/j.pharmr.2026.100120_bib492","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1126\/science.aad3369","article-title":"Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity","volume":"352","author":"Zhernakova","year":"2016","journal-title":"Science"},{"issue":"7695","key":"10.1016\/j.pharmr.2026.100120_bib493","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nature25973","article-title":"Environment dominates over host genetics in shaping human gut microbiota","volume":"555","author":"Rothschild","year":"2018","journal-title":"Nature"},{"issue":"6086","key":"10.1016\/j.pharmr.2026.100120_bib494","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1126\/science.1224203","article-title":"The application of ecological theory toward an understanding of the human microbiome","volume":"336","author":"Costello","year":"2012","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib495","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1194\/jlr.R049437","article-title":"Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades","volume":"55","author":"Hofmann","year":"2014","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib496","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.chom.2017.03.010","article-title":"The gut microbiome: connecting spatial organization to function","volume":"21","author":"Tropini","year":"2017","journal-title":"Cell Host Microbe"},{"issue":"7961","key":"10.1016\/j.pharmr.2026.100120_bib497","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41586-023-05989-7","article-title":"Profiling the human intestinal environment under physiological conditions","volume":"617","author":"Shalon","year":"2023","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib498","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/nbt.3981","article-title":"Assessment of variation in microbial community amplicon sequencing by the Microbiome Quality Control (MBQC) project consortium","volume":"35","author":"Sinha","year":"2017","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib499","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41564-018-0306-4","article-title":"Gut microbiome structure and metabolic activity in inflammatory bowel disease","volume":"4","author":"Franzosa","year":"2019","journal-title":"Nat Microbiol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100120_bib500","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tim.2017.11.002","article-title":"Human gut microbiome: function matters","volume":"26","author":"Heintz-Buschart","year":"2018","journal-title":"Trends Microbiol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib501","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GIM.0b013e318184137c","article-title":"The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group","volume":"11","author":"Teutsch","year":"2009","journal-title":"Genet Med"},{"issue":"7471","key":"10.1016\/j.pharmr.2026.100120_bib502","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature12564","article-title":"Criteria for the use of omics-based predictors in clinical trials","volume":"502","author":"McShane","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2026.100120_bib503","article-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource","year":"2016","journal-title":"Food and Drug Administration (US)"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib504","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrclinonc.2011.2","article-title":"Methodological and practical challenges for personalized cancer therapies","volume":"8","author":"Wistuba","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib505","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/diagnostics11010103","article-title":"Towards routine implementation of liquid biopsies in cancer management: it is always too early, until suddenly it is too late","volume":"11","author":"IJzerman","year":"2021","journal-title":"Diagnostics"},{"issue":"9972","key":"10.1016\/j.pharmr.2026.100120_bib506","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (flint): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2026.100120_bib507","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fphar.2018.00931","article-title":"Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH","volume":"9","author":"Al-Dury","year":"2018","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib508","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.cell.2018.08.047","article-title":"Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT","volume":"174","author":"Suez","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib509","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ajcn\/nqz042","article-title":"Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"110","author":"Sharpton","year":"2019","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib510","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1055\/s-0041-1731707","article-title":"Role of FXR in bile acid and metabolic homeostasis in NASH: pathogenetic concepts and therapeutic opportunities","volume":"41","author":"Radun","year":"2021","journal-title":"Semin Liver Dis"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib511","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/13543776.2018.1459569","article-title":"Farnesoid X receptor modulators 2014\u2013present: a patent review","volume":"28","author":"Sepe","year":"2018","journal-title":"Expert Opin Ther Pat"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib512","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/gutjnl-2016-313017","article-title":"European consensus conference on faecal microbiota transplantation in clinical practice","volume":"66","author":"Cammarota","year":"2017","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib513","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1128\/microbiolspec.BAD-0017-2017","article-title":"U.S. regulatory considerations for development of live biotherapeutic products as drugs","volume":"5","author":"Dreher-Lesnick","year":"2017","journal-title":"Microbiol Spectr"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100120_bib514","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib515","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2217\/pme-2016-0104","article-title":"Barriers to clinical adoption of next-generation sequencing: a policy Delphi panel\u2019s solutions","volume":"14","author":"Messner","year":"2017","journal-title":"Per Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib516","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100120_bib517","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s41579-019-0256-8","article-title":"Diet-microbiota interactions and personalized nutrition","volume":"17","author":"Kolodziejczyk","year":"2019","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib518","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/HEP.0000000000000387","article-title":"Single-cell and spatially resolved transcriptomics for liver biology","volume":"80","author":"Lin","year":"2024","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib519","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.cell.2016.05.041","article-title":"From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites","volume":"165","author":"Koh","year":"2016","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib520","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3201\/eid3008.240181","article-title":"Archaea in the human microbiome and potential effects on human infectious disease","volume":"30","author":"Duller","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.pharmr.2026.100120_bib521","article-title":"Gut phageome: challenges in research and impact on human microbiota","volume":"15","author":"Yu","year":"2024","journal-title":"Front Microbiol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib522","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012377","article-title":"Gut mycobiome alterations and implications for liver diseases","volume":"20","author":"Zeng","year":"2024","journal-title":"PLoS Pathog"},{"issue":"475","key":"10.1016\/j.pharmr.2026.100120_bib523","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7975","article-title":"An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans","volume":"11","author":"Kurtz","year":"2019","journal-title":"Sci Transl Med"},{"issue":"530","key":"10.1016\/j.pharmr.2026.100120_bib524","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax0876","article-title":"Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies","volume":"12","author":"Gurbatri","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharmr.2026.100120_bib525","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.copbio.2018.01.028","article-title":"Synthetic biology in probiotic lactic acid bacteria: at the frontier of living therapeutics","volume":"53","author":"Mays","year":"2018","journal-title":"Curr Opin Biotechnol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib526","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1124\/mol.110.064501","article-title":"Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist","volume":"78","author":"Rizzo","year":"2010","journal-title":"Mol Pharmacol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib527","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41401-022-00880-z","article-title":"Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease","volume":"43","author":"Jiao","year":"2022","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib528","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib529","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000450988","article-title":"Apical sodium-dependent transporter inhibitors in primary biliary cholangitis and primary sclerosing cholangitis","volume":"35","author":"Hegade","year":"2017","journal-title":"Dig Dis"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100120_bib530","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.molmet.2017.09.001","article-title":"Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice","volume":"6","author":"Jouihan","year":"2017","journal-title":"Mol Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib531","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including Cilofexor and Firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib532","doi-asserted-by":"crossref","DOI":"10.1093\/lifemeta\/loae029","article-title":"Potential therapeutic strategies for MASH: from preclinical to clinical development","volume":"3","author":"Xie","year":"2024","journal-title":"Life Metab"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib533","article-title":"Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease","volume":"7","author":"Schwabe","year":"2025","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib534","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4254\/wjh.v11.i6.489","article-title":"Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis","volume":"11","author":"Campion","year":"2019","journal-title":"World J Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib535","doi-asserted-by":"crossref","first-page":"17","DOI":"10.20517\/mrr.2023.44","article-title":"Microbiota-gut-liver-brain axis and hepatic encephalopathy","volume":"3","author":"Lu","year":"2024","journal-title":"Microbiome Res Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib536","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s40168-024-01924-8","article-title":"Akkermansia muciniphila improve cognitive dysfunction by regulating BDNF and serotonin pathway in gut-liver-brain axis","volume":"12","author":"Kang","year":"2024","journal-title":"Microbiome"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib537","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1039\/C7FO01528C","article-title":"Gut: liver: brain axis: the microbial challenge in the hepatic encephalopathy","volume":"9","author":"Mancini","year":"2018","journal-title":"Food Funct"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib538","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jceh.2018.06.008","article-title":"Role of peripheral inflammation in hepatic encephalopathy","volume":"8","author":"Azhari","year":"2018","journal-title":"J Clin Exp Hepatol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100120_bib539","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4161\/gmic.28684","article-title":"The role of microbiota in hepatic encephalopathy","volume":"5","author":"Bajaj","year":"2014","journal-title":"Gut Microbes"},{"key":"10.1016\/j.pharmr.2026.100120_bib540","article-title":"The role of intestinal bacteria and gut-brain axis in hepatic encephalopathy","volume":"10","author":"Chen","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib541","doi-asserted-by":"crossref","first-page":"203","DOI":"10.55782\/ane-2023-018","article-title":"Hyperammonemia induced gut microbiota dysbiosis and motor coordination disturbances in mice: new insight into gut-brain axis involvement in hepatic encephalopathy","volume":"83","author":"Abdelmohcine","year":"2023","journal-title":"Acta Neurobiol Exp"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib542","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/metabo13060772","article-title":"Gut microbiota and neuroinflammation in acute liver failure and chronic liver disease","volume":"13","author":"Giuli","year":"2023","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100120_bib543","article-title":"The neurogliovascular unit in hepatic encephalopathy","volume":"3","author":"Claeys","year":"2021","journal-title":"JHEP Rep"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib544","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s11011-024-01402-y","article-title":"Infection, inflammation and hepatic encephalopathy from a clinical perspective","volume":"39","author":"Ntuli","year":"2024","journal-title":"Metab Brain Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib545","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1525-1373.1999.d01-120.x","article-title":"Hepatic encephalopathy: an update of pathophysiologic mechanisms","volume":"222","author":"Hazell","year":"1999","journal-title":"Proc Soc Exp Biol Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100120_bib546","first-page":"352","article-title":"The direct contribution of astrocytes and microglia to the pathogenesis of hepatic encephalopathy","volume":"7","author":"Jaeger","year":"2019","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100120_bib547","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s11011-015-9746-1","article-title":"Pathogenesis of hepatic encephalopathy in cirrhosis: the concept of synergism revisited","volume":"31","author":"Butterworth","year":"2016","journal-title":"Metab Brain Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100120_bib548","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ajpath.2015.10.005","article-title":"Bile acid signaling is involved in the neurological decline in a murine model of acute liver failure","volume":"186","author":"McMillin","year":"2016","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100120_bib549","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/labinvest.2015.70","article-title":"TGFbeta1 exacerbates blood-brain barrier permeability in a mouse model of hepatic encephalopathy via upregulation of MMP9 and downregulation of claudin-5","volume":"95","author":"McMillin","year":"2015","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmr.2026.100120_bib550","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fncel.2017.00191","article-title":"Bile acid-mediated sphingosine-1-phosphate Receptor 2 signaling promotes neuroinflammation during hepatic encephalopathy in mice","volume":"11","author":"McMillin","year":"2017","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib551","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12974-016-0710-8","article-title":"Infliximab reduces peripheral inflammation, neuroinflammation, and extracellular GABA in the cerebellum and improves learning and motor coordination in rats with hepatic encephalopathy","volume":"13","author":"Dadsetan","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100120_bib552","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037825","article-title":"Gut microbiota metabolites and risk of major adverse cardiovascular events and death: a systematic review and meta-analysis","volume":"103","author":"Khan","year":"2024","journal-title":"Medicine"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100120_bib553","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186425","article-title":"Therapeutic horizons in metabolic dysfunction-associated steatohepatitis","volume":"135","author":"Newsome","year":"2025","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100120_bib554","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib555","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40364-025-00774-2","article-title":"The evolving landscape of biomarkers for systemic therapy in advanced hepatocellular carcinoma","volume":"13","author":"Guo","year":"2025","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100120_bib556","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.12786\/bn.2022.15.e4","article-title":"Nutrition management in patients with traumatic brain injury: a narrative review","volume":"15","author":"Lee","year":"2022","journal-title":"Brain Neurorehabil"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:12:05Z","timestamp":1777450325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699726000086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":556,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0031699726000086"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100120","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100120"}}